View : 198 Download: 0

Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares

Title
Current gout treatment and flare in South Korea: Prophylactic duration associated with fewer gout flares
Authors
Choi, Hyo JinLee, Chan HeeLee, Joo HyunYoon, Bo YoungKim, Hyoun AhSuh, Chang HeeChoi, Sang TaeSong, Jung SooJoo, Ho YeonChoi, Sung JaeLee, Ji SooShin, Kee ChulBaek, Han Joo
Ewha Authors
이지수
SCOPUS Author ID
이지수scopus
Issue Date
2017
Journal Title
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
ISSN
1756-1841JCR Link

1756-185XJCR Link
Citation
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES vol. 20, no. 4, pp. 497 - 503
Keywords
flaregout treatmentprophylactic durationserum uric acid
Publisher
WILEY
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Aim: To evaluate treatment patterns and clinical factors affecting gout flare in South Korea. Methods: We retrospectively examined data from 401 patients seen at nine rheumatology multicenter clinics, under urate lowering therapy (ULT) more than 6 months after stopping prophylactic medication. Demographic data, clinical and laboratory features were collected at the initiation of ULT, upon stopping prophylaxis, and 6 months after. Results: The mean age was 52.2 years and mean disease duration was 25.0 months. The male-to-female count was 387 : 14. The most common ULT starting agent was allopurinol 83.8%. Colchicine (62.3%) was the most commonly prescribed prophylactic agent. During ULT, 134 of the 401 patients (33.4%) experienced at least one gouty attack in the period from stopping prophylaxis to 6 months later. The duration of prophylaxis was different between those with serum uric acid levels below 6 mg/dL and those over 6 mg/dL (P = 0.001). Of the 179 patients (44.6%) who attained target serum uric acid (SUA) levels (6 mg/dL) at the end of prophylaxis, those taking < 6 months of prophylaxis suffered more frequent flares than those taking it >= 6 months (42.9% vs. 26.3%, P = 0.041). The time interval to the first attack after stopping prophylaxis was shorter in the < 6 months group than the >= 6 months group (13.5 weeks vs. 22.5 weeks, P = 0.007). Conclusions: Prophylaxis more than 6 months from initiation of ULT, and achieving target SUA (< 6 mg/dL) at the time of stopping prophylaxis is associated with fewer gout flares during ULT.
DOI
10.1111/1756-185X.12422
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE